Navigation Links
NeurogesX to Hold Conference Call to Discuss Third Quarter 2009 Financial Results
Date:10/30/2009

Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to: positive results in clinical trials may not be sufficient to obtain FDA approval; the FDA may request additional clinical trials or other information prior to granting approval for Qutenza; any regulatory approvals which are received may be limited to certain indications; NeurogesX' product candidates may have unexpected adverse side effects or inadequate therapeutic efficacy or tolerability; physician or patient reluctance to use Qutenza or NGX-1998, if approved; and other difficulties or delays in, clinical development of, and obtaining regulatory approval for NeurogesX' product candidates. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission.

    NeurogesX, Inc.                          The Ruth Group
    Stephen Ghiglieri                        Sara Pellegrino (investors)
    Chief Financial Officer                  (646) 536-7002
    (650)358-3310                            spellegrino@theruthgroup.com

                                             Jason Rando (media)
                                             (646) 536-7025
                                             jrando@theruthgroup.com

SOURCE NeurogesX, Inc.


'/>"/>
SOURCE NeurogesX, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. NeurogesX to Present at JMP Securities Healthcare Focus Conference
2. NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study
3. NeurogesX Receives FDA Orphan Drug Designation for Qutenza(TM) for Treatment of Postherpetic Neuralgia
4. NeurogesX Announces Publication of Phase 3 Data for QUTENZA(TM) (NGX-4010) in Postherpetic Neuralgia (PHN) by The Lancet Neurology
5. NeurogesX Initiates Dosing in Phase 1 Clinical Trial for NGX-1998 Capsaicin Liquid Formulation
6. NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology
7. NeurogesX Announces Preliminary Results from Second Phase 3 Clinical Trial in HIV-DSP
8. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
9. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
10. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
11. Beckman Coulter Announces Conference Call and Webcast of Accompanying Slides in Conjunction With Third Quarter 2009 Earnings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... CAMPBELL, Calif. , July 24, 2014 /PRNewswire/ ... the development of novel interventional devices to facilitate ... United States Patent and Trademark Office has issued ... core technology behind the company,s Lazarus Cover TM ... The Lazarus ReCover is a single-component stent-retriever ...
(Date:7/24/2014)... -- In any given hospital in the country at any ... one hospital-acquired infection, according to the Centers of Disease ... prove fatal. And as increased surveillance has shown that ... per year, infection control efforts have drifted to the ... stronger emphasis is being placed upon innovative and comprehensive ...
(Date:7/24/2014)... ANAHEIM, Calif., July 24, 2014 Questcor Pharmaceuticals, Inc. ... the second quarter ended June 30, 2014. Three Months Ended ... $278.8 Million , $184.6 Million , 51% Non-GAAP Net ... GAAP Diluted EPS , $1.54 , $1.12 ... , $1.35 , 37%  Six Months ...
Breaking Medicine Technology:Lazarus Effect Receives Notice of Allowance for New US Patent Covering Core Protection Technology 2Employees, Equipment and the Environment: Top Infection Prevention Focuses in Hospitals 2Employees, Equipment and the Environment: Top Infection Prevention Focuses in Hospitals 3Questcor Reports Record Second Quarter Financial Results 2Questcor Reports Record Second Quarter Financial Results 3Questcor Reports Record Second Quarter Financial Results 4Questcor Reports Record Second Quarter Financial Results 5Questcor Reports Record Second Quarter Financial Results 6Questcor Reports Record Second Quarter Financial Results 7Questcor Reports Record Second Quarter Financial Results 8Questcor Reports Record Second Quarter Financial Results 9Questcor Reports Record Second Quarter Financial Results 10Questcor Reports Record Second Quarter Financial Results 11Questcor Reports Record Second Quarter Financial Results 12Questcor Reports Record Second Quarter Financial Results 13Questcor Reports Record Second Quarter Financial Results 14Questcor Reports Record Second Quarter Financial Results 15Questcor Reports Record Second Quarter Financial Results 16Questcor Reports Record Second Quarter Financial Results 17Questcor Reports Record Second Quarter Financial Results 18Questcor Reports Record Second Quarter Financial Results 19Questcor Reports Record Second Quarter Financial Results 20Questcor Reports Record Second Quarter Financial Results 21Questcor Reports Record Second Quarter Financial Results 22Questcor Reports Record Second Quarter Financial Results 23Questcor Reports Record Second Quarter Financial Results 24Questcor Reports Record Second Quarter Financial Results 25Questcor Reports Record Second Quarter Financial Results 26Questcor Reports Record Second Quarter Financial Results 27Questcor Reports Record Second Quarter Financial Results 28
(Date:7/24/2014)... Exposure to light at night, which shuts off nighttime ... resistant to tamoxifen, a widely used breast cancer drug, ... Medicine cancer researchers. The study, "Circadian and Melatonin Disruption ... to Tamoxifen Therapy in Breast Cancer," published in the ... show that melatonin is vital to the success of ...
(Date:7/24/2014)... 24, 2014 Vulnerable populations such ... households are disproportionately affected by food security, despite ... in the United States, according to a new ... of the Consolidated Appropriations Act, 2014 (P.L. 113-76), ... and Nutrition Service (FNS) to contract with a ...
(Date:7/24/2014)... 2014 Just as fitness and health ... their own financial and marketing strength to be important ... to the next level by using the most powerful ... Voice Broadcast, Call Tracking and SMS texting solutions ... text messages are quickly become integral in marketing and ...
(Date:7/24/2014)... NJ (PRWEB) July 24, 2014 ... leading specialist in hematology and oncology, Dr. Hitendra ... Group. Our system welcomes Dr. Upadhyaya to the ... comprise CarePoint Health Medical Group, a comprehensive network ... representing a wide range of specialties. This latest ...
(Date:7/24/2014)... found a way to delay or even prevent Alzheimer,s ... the anti-aging protein Klotho can prevent neuron death in ... These findings currently appear in the Journal of ... most frequent age-related dementia affecting 5.4 million Americans including ... more than 40 percent of people over the age ...
Breaking Medicine News(10 mins):Health News:Total darkness at night is key to success of breast cancer therapy -- Tulane study 2Health News:Report: Vulnerable Populations Disproportionately Affected by Food Security, Despite Public Programs 2Health News:Report: Vulnerable Populations Disproportionately Affected by Food Security, Despite Public Programs 3Health News:Pump Up Your Gym’s Marketing Muscles with Mobile Marketing: CallFire's Health & Fitness Webinar Week – July 28th to August 1st 2Health News:Pump Up Your Gym’s Marketing Muscles with Mobile Marketing: CallFire's Health & Fitness Webinar Week – July 28th to August 1st 3Health News:Dr. Upadhyaya Joins CarePoint Health Medical Group 2Health News:BU researchers discover that Klotho is neuroprotective against Alzheimer's disease 2
... AMERIGROUP Corporation (NYSE: AGP ) today announced ... Healthcare Conference on May 18 in Boston.A live broadcast of ... Eastern Time, can be accessed on AMERIGROUP,s Web site, ... will be available for 30 days, and can be accessed ...
... could cut the death risk in half, study finds, , , ... just help others; it turns out, it probably benefits your ... less than half the risk of dying compared to their ... the American Geriatrics Society annual meeting, in Chicago. , ...
... May 8 The federal government has made tax ... companies with the implementation of simple automation into new ... incentives will have a positive impact on organizations purchasing ... while providing increased efficiencies and a high internal rate ...
... 8 Valeant Pharmaceuticals International (NYSE: VRX ... privately held company located in Poland for approximately $28 ... in Poland into multiple therapeutic categories. EMO-FARM has a ... a portfolio of currently marketed products and additional products ...
... JLL Partners, Inc. and its affiliate, JLL Patheon Holdings, ... (Toronto time) on May 7, 2009 (the "Expiry Time") 31,411,927 ... were validly deposited to JLL,s offer to acquire, at a ... the issued and outstanding Restricted Voting Shares of Patheon (the ...
... In the 25 years between 1981 and 2006 mortality rates ... remarkable 80% in men and women aged between 25 and ... Were the health services of Iceland so much better, or ... Dr Thor Aspelund and colleagues from the Icelandic Heart Association ...
Cached Medicine News:Health News:Seniors Who Volunteer May Live Longer 2Health News:Seniors Who Volunteer May Live Longer 3Health News:Valeant to Acquire Polish Dermatology Company 2Health News:JLL Announces Extension of Its Offer To Acquire Patheon and Take Up of Deposited Restricted Voting Shares 2Health News:JLL Announces Extension of Its Offer To Acquire Patheon and Take Up of Deposited Restricted Voting Shares 3Health News:Massive decline in rates of coronary death in Iceland are largely attributed to risk factor reductions in the population 2
... the detailed information you need to make ... with palpitations, syncope and intermittent chest pain., ... this transtelephonic cardiac event monitor requires just ... ECG. Comfortable for your patients to wear ...
... The MULTIVIEW WORKSTATION enhances patient care ... rapid assessment, decision support, and clinical ... Part of the INFINITY Patient Monitoring ... patient information, including continuous, real-time patient ...
... offers the ultimate PET/CT performance ... treatment in oncology, neurology, and ... whole body scans in less ... suite of clinical applications offers ...
... SOMATOM Sensation is the highly respected single-source ... branches to visualizing plaque. With its proprietary ... fastest rotation time of 0.33s, virtually freezing ... Technology, the system delivers unprecedented diagnostic detail ...
Medicine Products: